William K. Schmidt, PhD Joins Urigen’s SAB
2010-02-17 09:25 ET - News Release
SAN FRANCISCO -- (Business Wire)
Urigen Pharmaceuticals, Inc. (OTCBB:URGP), a specialty pharmaceutical company focused on the development of treatments for urological disorders and pain, announced today that William K. Schmidt, PhD has joined Urigen’s Scientific Advisory Board.
“Dr. Schmidt, a pharmacologist, has been a consultant to Urigen since 2006 assisting with development strategy for URG101,” said Urigen’s CEO William J. Garner, MD. “His experience includes the development of Combunox®, a combination pain product and other pain products.”
